Vasopressin receptor antagonists. - Wikidata - awgldk - TriplyDB

Vasopressin receptor antagonists.

Vasopressin receptor antagonists.

http://www.wikidata.org/entity/Q38325590

about

Metabolic effects of resistance or high-intensity interval training among glycemic control-nonresponsive children with insulin resistance.

P2860

Q47554905-855F3310-E1B4-4610-97AE-0C146D595150

P2860

Vasopressin receptor antagonists.

http://www.wikidata.org/entity/Q38325590

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Vasopressin receptor antagonists.

@en

type

label

Vasopressin receptor antagonists.

@en

prefLabel

Vasopressin receptor antagonists.

@en

P1433

Q38325590-95D7BD89-536F-4993-86CE-AB2A23105058

P1476

Q38325590-74F0D1E1-C270-4644-A51D-1FA859B2EADC

P2093

Q38325590-BA2EE924-872C-41BB-80A7-56A3A6307906

P2860

Q38325590-0F1088D4-274F-459A-ABEB-E0AD7321D6BC

Q38325590-11BF4E77-9F5D-4ECF-B25C-1CCE1D3E2EF7

Q38325590-260B746D-437F-4730-9D13-5710AC35DB49

Q38325590-2726246A-970C-4C9B-8C67-DF5751ABDC1E

Q38325590-29C7D248-5764-4CFC-9136-E962D11FB295

Q38325590-2DBC5D2E-7C3F-49A0-BD30-CAA79103C6B7

Q38325590-35946D89-3F25-4030-89F5-698A9B355F2C

Q38325590-3706E3FD-FB4F-4119-AAFD-E0B22EDE2BF6

Q38325590-407D03BD-FE7F-426E-9B8C-74297CE2AAA9

Q38325590-419EBAB3-D6CA-43E8-9F78-0CB11B11FF21

P2888

Q38325590-BDA2DF4B-AD63-41A0-A89F-46818D1D3452

P304

Q38325590-7AAA8D09-B0A0-4E5F-A790-A634929A2207

P31

Q38325590-7CA44055-5BAD-4532-A56A-E9711F10B6B7

P356

Q38325590-ECF9EAFB-D263-4B21-AEB9-0364B37B1A4A

P433

Q38325590-B2E40914-EC1A-4BBE-AF07-B5F28AAC3A9D

P478

Q38325590-5D271D66-99F7-401E-A6D7-5DD1B6A6103C

P577

Q38325590-02876EB9-904B-44A3-A632-7B3EA098A25D

P6179

Q38325590-9AD261DF-D4E3-4509-9F3F-CCC18525BAFB

P698

Q38325590-C54D15BE-30C1-44C0-B5C8-559FED23213B

P921

Q38325590-f2d253c5-4226-482d-be5b-501eae248ecd

P356

S11906-014-0510-4

P1433

Current Hypertension Reports

P1476

Vasopressin receptor antagonists.

@en

P2093

Biff F Palmer

http://www.w3.org/2001/XMLSchema#string

P2860

Vasopressin V1a and V1b receptors: from molecules to physiological systems

Adenylyl cyclase 6 enhances NKCC2 expression and mediates vasopressin-induced phosphorylation of NKCC2 and NCC

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

The contributions of oxytocin and vasopressin pathway genes to human behavior.

Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit

Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.

Oral tolvaptan is safe and effective in chronic hyponatremia

Hyponatraemia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting.

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Endolymphatic hydrops: pathophysiology and experimental models.

P2888

s11906-014-0510-4

P304

510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11906-014-0510-4

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014248586

http://www.w3.org/2001/XMLSchema#string

P698

25604388

http://www.w3.org/2001/XMLSchema#string

P921